Pharmaceutical Technology recently interviewed Lisa Crandall, MS, and Peter Angus, PhD, from Velesco Pharma, delving into the critical topic of determining drug stability in pharmaceutical development. The discussion shed light on various best practices and methodologies employed in stability testing to ensure the efficacy and safety of API and drug products.
In the early stages of development, stability analysis involves assessing crucial parameters such as appearance, assay, related substances, and water content. Additionally, depending on the formulation under evaluation, tests like preservative assay, pH measurement, and antimicrobial effectiveness may be necessary. Techniques such as high-performance liquid chromatography (HPLC) are commonly utilized for analyzing impurities. As the product advances towards later stages of development, while the stability indicating techniques remain consistent, there is a shift towards more advanced methods for quantifying known impurities.
Ensuring the stability of a drug product requires meticulous attention to detail regarding the impact of environmental factors like temperature, humidity, and light, as well as considerations of polymorphs, salt forms, excipient compatibility, and packaging. Early identification of limitations and interactions is crucial for optimizing product stability, especially when specific polymorphs display varying degrees of stability.
One of the common pitfalls encountered in early development is the oversight of conducting comprehensive risk assessments in alignment with international guidelines such as ICH Q8 and Q9. Insufficient emphasis on designing a quality product from the outset can lead to stability issues down the line. Proactive planning and foreknowledge can help mitigate potential challenges by integrating considerations related to synthetic routes, formulations, packaging, and storage early in the development process.
To enhance the likelihood of achieving a stable and successful product, it is imperative to structure early-phase experiments to gather comprehensive insights into the API and the product characteristics. As the development progresses, leveraging existing data to make informed decisions regarding synthetic routes, formulations, manufacturing processes, and analytical methodologies becomes paramount for optimizing stability and quality.
In the dynamic landscape of biotech manufacturing operations, maximizing drug stability is a multifaceted endeavor that demands a strategic approach and adherence to best practices. By fostering strong partnerships with reputable CDMOs and staying abreast of industry advancements, companies can navigate the complexities of drug development more effectively. Collaborative efforts and knowledge-sharing among key stakeholders play a pivotal role in driving innovation and ensuring the delivery of safe and efficacious drug products to patients worldwide.
Key Takeaways:
– Early identification of stability issues through comprehensive testing and analysis is crucial for optimizing product stability.
– Adherence to international guidelines and best practices in risk assessment is essential to prevent stability-related challenges in drug development.
– Proactive planning and continuous data utilization throughout the development process are critical for enhancing product stability and quality.
Tags: chromatography, formulation, analytical methods
Read more on pharmtech.com